Prevalence of High Risk Human Papillomavirus Infection with Different Cervical Cytological Features among Women Undergoing Health Examination at the National Cancer Institute, Thailand

  • Published : 2014.07.30


High-risk (HR) human papillomavirus (HPV) testing is important in cervical cancer screening for triage colposcopy. The objective of the study was to evaluate the prevalence of HR HPV infection with different cervical cytological features among women undergoing health examination. A total of 2,897 women were retrospectively evaluated between May 2011 to December 2011. DNA was extracted from residual specimens collected during routine liquid-based cytology tests at the National Cancer Institute. Overall, HR HPV prevalence was 9.3% including 1.6% of HPV-16 and 0.4% of HPV-18. Of all 270 HPV positive samples, 211 (78.1% were HR-HPV non 16/18; 47 (17.4%) were HPV-16 and 12 (4.4%) were HPV-18. The prevalence of HPV infection was similar in all age groups, although a higher rate was observed in women age 31-40 years. Among women with normal cytology, HR HPV positive were found in 6.7%. In abnormal cytology, HR HPV were found 46.7% in atypical squamous cells (ASC), 54.8% in low-grade squamous intraepithelial lesions (LSIL) and 80.0% in high-grade squamous intraepithelial lesions (HSIL). HPV-16 was detected in 8.6%, 6.4% and 12.0% of ASC, LSIL and HSIL, respectively. The results of this study provide baseline information on the HPV type distribution, which may be useful for clinicians to decide who should be monitored or treated more aggressively.



  1. Bao YP, Li N, Smith JS, Qiao YL (2008). ACCPAB members. Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer, 18, 71-9.
  2. Burd E (2003). Human papillomavirus and cervical cancer. Clin Microbiol Rev, 16, 1-17.
  3. Clifford GM, Gallus S, Herrero R, et al (2005). Worldwide distribution of human papillonavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet, 366, 991-8.
  4. Coupe VMH, Berkhof J, Bulkmans NW, Snijders PJ, Meijer CJ (2008). Age dependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer, 98, 646-51.
  5. Day SP, Hudson A, Mast A, et al (2009). Analytical performance of the investigational use only Cervista HPV HR test as determined by a multi-center study. J Clin Virol, 45, 63-72.
  6. Argyri E, Stefanos Papaspyridakos, Elpida Tsimplaki, et al (2013). A cross sectional study of HPV type prevalence according to age and cytology. BMC Infectious Diseases, 13, 53.
  7. International Agency for Research on Cancer (2005). IARC/ WHO handbooks of cancer prevention. Vol 10: cervix cancer screening. IARC Press.
  8. International Agency for Research on Cancer (2007). IARC monographs on the evaluation of carcinogenic risks to humans. Vol 90: human papillomaviruses. IARC Press.
  9. Kjaer SK, van den Brule AJC, Paull G, et al (2002). Type-specific persistence of high-risk human papillomavirus (HPV) is the major indicator of high-grade cervical squamous intraepithelial lesions (SIL) in 20-29 years old women. BMJ, 325, 572-3.
  10. Khuhaprema, T, Attasara P, Sriplung H, et al (2013). Cancer incidence in Thailand 2007-2009. National Cancer Institute. Bangkok, Thailand.
  11. Natphopsuk S, Settheetham-Ishida W, Pientong C, et al (2013). Human papillomavirus genotypes and cervical cancer in northeast Thailand. Asian Pac J Cancer Prev, 14, 6961-4.
  12. Ngamkham J, Homcha-Aim P, Boonmark K, Phansri T, Swangvaree SS (2013). Preliminary study on human papillomavirus frequency and specific type-distribution in vulva cancer from Thai women. Asian Pac J Cancer Prev, 14, 2355-9.
  13. Schlect NF, Kulafa S, Robitaille J, et al (2001). Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA, 286, 3106-14.
  14. Siriaunkgul S, Settakorn J, Sukpan K, et al (2014). HPV detection and genotyping in vulvar squamous cell carcinoma in northern Thailand. Asian Pac J Cancer Prev, 15, 3773-8.
  15. Sukvirach S, Smith JS, Tunsakul S, et al (2003). Populationbased human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis, 187, 1246-56.
  16. Swangvaree SS, Kongkaew P, Ngamkham J (2013). Frequency and type-distribution of human papillomavirus from paraffinembedded blocks of high grade cervical intraepithelial neoplasia lesions in Thailand. Asian Pac J Cancer Prev, 14, 1023-6.
  17. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.<12::AID-PATH431>3.0.CO;2-F
  18. Woodman CB, Collins S, Winther H, et al (2001). Natural history of cervical human papillomavirus in young women: a longitudinal cohort study. Lancet, 357, 1831-6.
  19. Wright TC, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ (2002). 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA, 287, 2120-9.

Cited by

  1. Performance of HPV DNA Testing with Hybrid Capture 2 in Triaging Women with Minor Cervical Cytologic Abnormalities (ASC-US/LSIL) in Northern Thailand vol.15, pp.24, 2014,